{"altmetric_id":1587786,"counts":{"readers":{"mendeley":42,"citeulike":0,"connotea":0},"policy":{"unique_users_count":1,"unique_users":["nice"],"posts_count":1},"total":{"posts_count":2},"twitter":{"unique_users_count":1,"unique_users":["zeneconomicss"],"posts_count":1}},"citation":{"abstract":"Multiple sclerosis (MS) is a highly debilitating immune mediated disorder and the second most common cause of neurological disability in young and middle-aged adults. Iran is amongst high MS prevalence countries (50\/100,000). Economic burden of MS is a topic of important deliberation in economic evaluations study. Therefore determining of cost-effectiveness interferon beta (INF \u03b2) and their copied biopharmaceuticals (CBPs) and biosimilars products is significant issue for assessment of affordability in Lower-middle-income countries (LMICs).","abstract_source":"pubmed","altmetric_jid":"4f6fa53d3cf058f61000475b","authors":["Shekoufeh Nikfar","Abbas Kebriaeezadeh","Rassoul Dinarvand","Mohammad Abdollahi","Mohammad-Ali Sahraian","David Henry","Ali Akbari Sari"],"doi":"10.1186\/2008-2231-21-50","first_seen_on":"2013-06-27T10:02:22+00:00","issns":["1560-8115","2008-2231"],"issue":"1","journal":"DARU","last_mentioned_on":1474625985,"links":["http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/23800250?dopt=Abstract","http:\/\/dx.doi.org\/10.1186\/2008-2231-21-50"],"pdf_url":"http:\/\/darujps.biomedcentral.com\/track\/pdf\/10.1186\/2008-2231-21-50?site=darujps.biomedcentral.com","pmid":"23800250","pubdate":"2013-06-22T00:00:00+00:00","publisher":"BioMed Central","publisher_subjects":[{"name":"Pharmacology And Pharmaceutical Sciences","scheme":"era"}],"scopus_subjects":["Life Sciences","Pharmacology, Toxicology and Pharmaceutics"],"startpage":"50","title":"Cost-effectiveness of different interferon beta products for relapsing-remitting and secondary progressive multiple sclerosis: Decision analysis based on long-term clinical data and switchable treatments.","type":"article","volume":"21","mendeley_url":"http:\/\/www.mendeley.com\/research\/costeffectiveness-different-interferon-beta-products-relapsingremitting-secondary-progressive-multip-2"},"altmetric_score":{"score":3.5,"score_history":{"1y":0,"6m":0,"3m":0,"1m":0,"1w":0,"6d":0,"5d":0,"4d":0,"3d":0,"2d":0,"1d":0,"at":3.5},"context_for_score":{"all":{"total_number_of_other_articles":8422812,"mean":7.0866213065837,"rank":2008812,"this_scored_higher_than_pct":75,"this_scored_higher_than":6375868,"rank_type":"exact","sample_size":8422812,"percentile":75},"similar_age_3m":{"total_number_of_other_articles":126318,"mean":7.0711152576456,"rank":30499,"this_scored_higher_than_pct":75,"this_scored_higher_than":95070,"rank_type":"exact","sample_size":126318,"percentile":75},"this_journal":{"total_number_of_other_articles":31,"mean":2.1382,"rank":5,"this_scored_higher_than_pct":83,"this_scored_higher_than":26,"rank_type":"exact","sample_size":31,"percentile":83},"similar_age_this_journal_3m":{"total_number_of_other_articles":3,"mean":2.425,"rank":2,"this_scored_higher_than_pct":33,"this_scored_higher_than":1,"rank_type":"exact","sample_size":3,"percentile":33}}},"demographics":{"poster_types":{"member_of_the_public":1},"users":{"twitter":{"cohorts":{"Members of the public":1}},"mendeley":{"by_status":{"Unspecified":2,"Researcher":6,"Student  > Doctoral Student":3,"Student  > Ph. D. Student":10,"Student  > Postgraduate":2,"Student  > Master":11,"Other":2,"Student  > Bachelor":3,"Professor":3},"by_discipline":{"Medicine and Dentistry":12,"Neuroscience":3,"Social Sciences":4,"Psychology":2,"Economics, Econometrics and Finance":6,"Agricultural and Biological Sciences":4,"Computer Science":2,"Nursing and Health Professions":1,"Business, Management and Accounting":1,"Unspecified":4,"Pharmacology, Toxicology and Pharmaceutical Science":3}}},"geo":{"mendeley":{"TR":1,"IR":1,"BR":2}}},"posts":{"twitter":[{"url":"http:\/\/twitter.com\/zeneconomicss\/statuses\/350192344492019714","license":"public","citation_ids":[1587786],"posted_on":"2013-06-27T10:02:15+00:00","author":{"name":"zeneconomicss","image":"https:\/\/pbs.twimg.com\/profile_images\/2046940554\/scarlett-johansson-9_normal.jpg","description":"Zen Economics","id_on_source":"zeneconomicss","tweeter_id":"546521838","geo":{"lt":null,"ln":null},"followers":279},"tweet_id":"350192344492019714"}],"policy":[{"title":"Daclizumab for treating relapsing\u2013remitting multiple sclerosis: Committee papers","url":"https:\/\/www.nice.org.uk\/guidance\/ta441\/documents\/committee-papers","license":"public","citation_ids":[6303623,7560147,1786002,744074,1610472,491878,2364176,1550591,3971332,1105649,4485333,596604,5903837,4515648,5409127,1337773,4600689,3163694,518469,2196786,1666787,19493202,2318253,226532,2067172,15773093,1358426,173606,1034350,1034351,2132895,3410402,2552104,15773089,8443358,15032127,4588772,3691485,2056919,19703988,2413987,865046,1552793,1827463,5041866,1337773,19703990,19493127,19703991,19703992,19703993,1859724,19703995,180407,19703996,19703997,7435160,4600689,19704000,1284803,2264038,981807,679334,15773093,1939353,15775689,1243688,15781485,1034351,1034350,1358429,393184,229205,955260,2698806,518864,2552104,1358426,19493131,19493197,1249257,229018,5568910,2318253,1132542,1319844,2200447,19704002,2122127,8204270,3352411,15775789,15784443,19704003,2862431,1851679,21735713,2796473,19704005,4500292,1455595,1552794,19704007,19704009,1489768,1977366,6466101,5087354,1212175,1878867,1236572,2364116,19493161,2793982,19704013,1231806,2456434,2875336,2973399,19704014,860485,2129826,19704015,6342626,6466088,19704018,2462309,577225,15775682,19704019,2446921,19493169,194003,1587786,4933051,4130277,1078089,19704023,16330952,19704025,21735731,14730384,21735734,2298229,19704028,19704029,19704030,19493171,854772,7404749,7404750,19704031,19704032,19704033,19704034,19704037,1610472,3154781,572267,537989,6434545,537988,6706650,19704042,19704043,2396544,19704044,19704045,771604,19704046,1304734,375069,3281286,527278,19704047,19493191,2786896,1437954,6466106,6466117,2436397,2039277,19704048,1530564,466479,991181,2031859,4195783,1501249,790426,15773077,19704052,19704054,5309374,19704060,19704061,19704064,7486213,7486215,6046194,16871322,19704072,19493247,4691917,19493244,19704073,19704074,19704076,19704077,19704078,19704079,19704080,19704081,19704083,15775731,19704086,4691915,4691916,15775757,15775754,15775761,15775745,19704090,19704091,19704092,19704093,17406692,4684070,4684074,19704097,19704098,1786002,1337773,4600689,2196786,1666787,2318253,2067172,173606,1034350,1034351,2132895,15773089,4195783,845362,865046,6308145,1552793,2883950],"posted_on":"2016-09-23T10:19:45+00:00","source":{"name":"National Institute for Health and Care Excellence","description":"The National Institute for Health and Care Excellence (NICE) in the UK provides national guidance and advice to improve health and social care.","geo":{"country":"GB"}},"page_url":"https:\/\/www.nice.org.uk\/guidance\/ta441\/evidence","collections":[],"author":{"image":"https:\/\/s3.amazonaws.com\/cache.altmetric.com\/policy\/thumbnails\/thumbnail-6346993c9455b6d102185409b579b4d621408396418373b479e88ce189ed13f0.jpg"}}]}}